PEB - Pacific Edge Ltd

[skid]

Hi Carpenterjoe,

It’s a single 2,000 patient user programme for Cxbladder(triage) only, per page nine of the recent presentation,

https://www.nzx.com/files/attachments/209911.pdf

Kaiser Permanente allocated staff late last year;

http://www.kp-scalresearch.org/Resea...t.aspx?eid=271

Pacific Edge have indicated that the user programme will complete this year, my feel is that it will probably be wrapped up and fully completed in the second half of the year, by which time all the results have been assessed, are ready for release, and a publication has been prepared and reviewed.

It may come with a concurrent KP sign up announcement too, so the schedule may be with KP, when they decide they are all good to go commercially.

For a significant clinical utility study like this we should anticipate that the outcomes should be published for the insurers to access, well, and for keen shareholders too.

kind regards, Mac

The User Program research is scheduled to begin later this year with results
completed in early 2015.(from initial report)

Just curious why you say the second half of the year-Am I missing something?

[psychic]

Presumably the beloved professor is now up to date on advances in cxbladder triage as this is the meeting highlighted on Pacific Edge's website under Calendar of Events. Do PEB actually attend these meetings because I see they are listed as healthcare exhibitions? If not, why not? If they do attend, loyal shareholders might be interested to know how it went.
Some word of mouth from cxbladder converted urologists at these bunfights would surely be spreading by now or are we still struggling with the almighty "dissonance" in Australia.

"Tear down this wall, Mr Darling."
(With apologies to Ronald Reagan)

Pity but looks as if you needed to submit and have approved any poster/ abstract presentation by Nov last year, so not possible to air the triage study I suppose.
But maybe the recent increased buying (yesterdays light trading excepted) came from those stopping by the PEB stand.?

[Minerbarejet]

Pity but looks as if you needed to submit and have approved any poster/ abstract presentation by Nov last year, so not possible to air the triage study I suppose.
But maybe the recent increased buying (yesterdays light trading excepted) came from those stopping by the PEB stand.?

Ah well, there is always next year. Hope the prof has a handle on it by then.

[skid]

It appears that registration for exhibitors is still open for the American Urologist Ass. conference--Is there any way to find out if PEB is exhibiting? (much more ex poser)


PS--congrates on your CDY holding,Miner--(now thats the kind of thing that catches attention)

[Snow Leopard]

The User Program research is scheduled to begin later this year with results
completed in early 2015.(from initial report)

Just curious why you say the second half of the year-Am I missing something?

PEB are basically very poor at communicating to their shareholders - this is definitely a bad thing.
But at the same time you are not keeping up with the game here.

They issue an announcement that gives the reader a definite impression and then some time later another announcement which provides a different impression.

This is in addition to the bi-annual spot the error in the financial statements that they run.

Plus there is more that I am not even going to bring up.


Anyway the most recent version of the 'truth' from PEB: page 9, left hand side, third block down.

Best Wishes
Paper Tiger

[winner69]

Successful commercialisation = bring to market

Making money (profit) is not part of the equation

The Darling definition

[Ginger_steps_]

It appears that registration for exhibitors is still open for the American Urologist Ass. conference--Is there any way to find out if PEB is exhibiting? (much more ex poser)


PS--congrates on your CDY holding,Miner--(now thats the kind of thing that catches attention)

Why don't you email them and ask? It wouldn't be the first time a ST member has tipped them off on an important event!

[skid]

PEB are basically very poor at communicating to their shareholders - this is definitely a bad thing.
But at the same time you are not keeping up with the game here.

They issue an announcement that gives the reader a definite impression and then some time later another announcement which provides a different impression.

This is in addition to the bi-annual spot the error in the financial statements that they run.

Plus there is more that I am not even going to bring up.


Anyway the most recent version of the 'truth' from PEB: page 9, left hand side, third block down.

Best Wishes
Paper Tiger

Your right -I guess Ive not been keeping up with the game--could some one help me out here?--six months from when?(news letter dated March 2015)

Is any one anticipating groundbreaking numbers in the next report that send the SP soaring?

Not saying it wont happen at some stage (if all goes well) but it still seems a bit early in the game to me(considering that some sort of catalyst is most likely needed.)

If Kaiser does come through,I guess its a matter of how much credit is given back to the ''potential'' scenario (as we of course wont know how it affects the numbers yet)

Im a bit surprised that no one has taken any notice of the fact that CMS cut its reimbursement for Urovysion by 50% as they thought it was to expensive (It was the only game in town at the time) which i suppose could be a debate for both camps (in terms of if that is good or bad news for other tests and their coverage)----the pros--it wont happen to new tests because there is no longer a monopoly ---the cons--If new test are also expensive (in the same ballpark)maybe they will get cuts as well or only get partial coverage.

[Minerbarejet]

Time is nearly up on this 400 patient evaluation for triage of microhaematuria presenters in NZ.
Interesting to note that Triage was launched in NZ in December well prior to the intended completion of this evaluation.
Also interesting is the launch of Triage in the US in JUNE this year.
A connection between the NZ evaluation results and the US Launch perhaps?
And you wonder why everything takes so long.



MidCentral DHB first in New Zealand to utilise Cxbladder

Posted on May 30th, 2013
NZX ANNOUNCEMENT: Released 30 May 2013
MidCentral District Health Board, based in Palmerston North, is set to become the first district health board in New Zealand to become a commercial customer for Pacific Edgeʼs diagnostic cancer test Cxbladder. MidCentral will be looking to provide patients with a better clinical outcome as well as make considerable savings and efficiencies from its use.
Beginning in June,(presumably 2013) MidCentral DHB will begin evaluating 400 patients over a 24-month period ( ending June 2015) to determine the clinical utility of Cxbladder to prioritise at-risk patients, and establish the level of savings that can be achieved from screening out patients who do not need a full and expensive urological work up for bladder cancer. Typically less than five percent of those patients who present to their clinician with micro-haematuria (non-visible blood in urine of clinical significance) will be diagnosed with bladder cancer.


Pacific Edge Chief Executive Officer David Darling says MidCentral DHBʼs goal is to triage patients early by utilising Cxbladder – a test that enables the detection of bladder cancer from a small volume of urine. Results from peer reviewed multi-centre clinical trials of 485 patients published in the prestigious Journal of Urology in the United States last year showed that Cxbladder outperformed all other benchmark technologies and identified nearly all tumours of interest to clinicians.
A full clinical work-up for bladder cancer is estimated to cost up to $2000. If conservatively, 80 percent of patients presenting with micro-haematuria can avoid the distress and inconvenience of a full bladder cancer evaluation, the cost savings for MidCentral DHB would be significant and would enable the more efficient use of DHB urological, clinical and pathology services.”

[skid]

I was beginning to wonder if anyone was still at home.